Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
Pathogenic variants in HRR genes can be a risk factor for anthracycline-induced cardiotoxicity
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available
Are we getting closer to apply AI-based techniques in clinical practice?
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
Building a lasting foundation for precision oncology
While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients.
Can telehealth be a genuine replacement for face-to-face healthcare?
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
Enhanced patient participation in trials may help make cancer research more heterogeneous
In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials
What level of evidence do we need for drug approval in rare cancers?
Achieving clarity in levels of clinical evidence required by regulatory bodies is still a major obstacle to expediting research in the field, says Prof. Paolo G. Casali from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and the University of Milan, Italy
Cancer Research
Food for thought: dietary effects on tumour metabolism and progression
Thanks to our deeper understanding of the underlying biology and molecular mechanisms that govern cancer, we are gaining important ground in tackling the myriad mediators of this disease.
New immunotherapies are explored to improve the treatment of solid tumours
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed